$530 for a five-day course of Paxlovid is not “attractive”. It’s extractive.

It’s well past time to listen to @DeanBaker13 and find ways for the public to cover the high fixed costs of drug development and let pill price fall to marginal cost. High fixed costs are not a justification for profiteering under patent monopolies.

from @hannah_rect@twitter.com khn.org/news/article/paxlovid-